BridgeBio Pharma, Inc. BBIO
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Raghuram Selvaraju | H.C. Wainwright | 51.505 $ | 70 $ | 18.50 % | 29/08/2025 |
| Eliana Merle | UBS | 38.36 $ | 72 $ | 33.64 % | 30/04/2025 |
| David Lebowitz | Citigroup | 24.17 $ | 45 $ | 20.83 % | 24/10/2024 |
| Mani Foroohar | Leerink Partners | 26.34 $ | 46 $ | 19.66 % | 17/10/2024 |
| Biren Amin | Piper Sandler | 28.78 $ | 46 $ | 17.22 % | 11/09/2024 |
| Salim Syed | Mizuho Securities | 29.92 $ | 53 $ | 23.08 % | 03/09/2024 |
| Danielle Brill | Raymond James | 22.645 $ | 46 $ | 23.36 % | 24/06/2024 |
| Kostas Biliouris | BMO Capital | 26.925 $ | 37 $ | 10.08 % | 05/06/2024 |
| Tiago Fauth | Wells Fargo | 27.13 $ | 58 $ | 30.87 % | 05/06/2024 |
| Paul Choi | Goldman Sachs | 27.61 $ | 50 $ | 22.39 % | 30/05/2024 |
| Eliana Merle | UBS | 27.94 $ | 47 $ | 19.06 % | 28/05/2024 |
| Raghuram Selvaraju | H.C. Wainwright | 30.09 $ | 43 $ | 12.91 % | 20/05/2024 |
| Cory Kasimov | Evercore ISI | 28.5 $ | 50 $ | 21.50 % | 13/05/2024 |
| Dane Leone | Raymond James | 10.76 $ | 17 $ | 6.24 % | 17/03/2022 |